Karen A. Cashmere's most recent trade in ZyVersa Therapeutics Inc was a trade of 48,100 Stock Options done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 48,100 | 48,100 | - | - | Stock Options | |
| ZyVersa Therapeutics Inc | A. Cashmere Karen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 572 | 572 | - | - | Stock Options | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 29,781 | 29,781 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 21,840 | 21,840 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 21,840 | 21,840 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 19,854 | 19,854 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 9,927 | 9,927 | - | - | Stock Options (right to buy) |